載入...
Orally administered anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel anti-inflammatory personalized therapeutic approach
Personalized therapies are designed to optimize the safety-to-efficacy ratio by selecting patients with higher response rates based on specific biomarkers. Inflammation plays a vital role in the pathogenesis of non-alcoholic steatohepatitis (NASH), a common liver disorder. Eotaxin-1 plays a role in...
Na minha lista:
| 發表在: | Int J Immunopathol Pharmacol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8287423/ https://ncbi.nlm.nih.gov/pubmed/34275345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20587384211021215 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|